Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer-Reply

Affiliations

¹ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick.
² Merck & Co Inc, Kenilworth, New Jersey.
³ LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.

Comment

Salma K Jabbour et al. JAMA Oncol. 2022.

. 2022 Jan 1;8(1):168-169.

doi: 10.1001/jamaoncol.2021.5611.

¹ Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick.
² Merck & Co Inc, Kenilworth, New Jersey.
³ LungenClinic, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.

No abstract available

Comment on

Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial.
Jabbour SK, Lee KH, Frost N, Breder V, Kowalski DM, Pollock T, Levchenko E, Reguart N, Martinez-Marti A, Houghton B, Paoli JB, Safina S, Park K, Komiya T, Sanford A, Boolell V, Liu H, Samkari A, Keller SM, Reck M. Jabbour SK, et al. JAMA Oncol. 2021 Jun 4;7(9):1-9. doi: 10.1001/jamaoncol.2021.2301. Online ahead of print. JAMA Oncol. 2021. PMID: 34086039 Free PMC article.
Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Tian L, Huang B, Wei LJ. Tian L, et al. JAMA Oncol. 2022 Jan 1;8(1):167-168. doi: 10.1001/jamaoncol.2021.5605. JAMA Oncol. 2022. PMID: 34734980 Free PMC article. No abstract available.
Analysis of Outcomes With Addition of Immunotherapy to Chemoradiation Therapy for Non-Small Cell Lung Cancer.
Kapoor A, Prabhash K. Kapoor A, et al. JAMA Oncol. 2022 Jan 1;8(1):168. doi: 10.1001/jamaoncol.2021.5608. JAMA Oncol. 2022. PMID: 34734982 No abstract available.